Search

Your search keyword '"Pugh, Trevor J."' showing total 1,112 results

Search Constraints

Start Over You searched for: Author "Pugh, Trevor J." Remove constraint Author: "Pugh, Trevor J."
1,112 results on '"Pugh, Trevor J."'

Search Results

1. Evaluation of methods to assign cell type labels to cell clusters from single-cell RNA-sequencing data

2. FAM72A degrades UNG2 through the GID/CTLH complex to promote mutagenic repair during antibody maturation

4. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment

6. “I just wanted more”: Hereditary cancer syndromes patients’ perspectives on the utility of circulating tumour DNA testing for cancer screening

8. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

9. Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours

10. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

11. Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

12. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities

13. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

15. Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data

16. Genome screening, reporting, and genetic counseling for healthy populations

17. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

18. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

19. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.

20. Failure of human rhombic lip differentiation underlies medulloblastoma formation

21. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy

22. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

23. Evaluation of methods to assign cell type labels to cell clusters from single-cell RNA-sequencing data.

25. Author Correction: Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape

27. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.

28. Prediction of acute myeloid leukaemia risk in healthy individuals.

29. Coenzyme A fuels T cell anti-tumor immunity

30. Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

31. Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

35. Supplementary Figures S1-S5 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium

36. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium

37. Figure S3 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA

38. Abstract B001: Identification of monoallelic ATM loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy

40. A distinct innate lymphoid cell population regulates tumor-associated T cells

41. Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers

43. Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity

44. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis

45. Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation

46. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel

47. Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA

48. Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy

49. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

Catalog

Books, media, physical & digital resources